Stocks · News reference
BB Biotech has initiated a new investment position in clinical-stage biopharmaceutical company LB Pharmaceuticals as part of its portfolio strategy.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
LB Pharmaceuticals announced its financial results for the third quarter of 2026, reporting a net loss of $59.1 million and a cash position of $403.8 million.
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
LB Pharmaceuticals Inc announced equity awards to newly appointed Chief Medical Officer Dr. Susan G. Kozauer and Chief Financial Officer Joseph Miller. Each executive received options to purchase 200,000 shares at an exercise price of $37.22, vesting over 4 years with a 10-year term. The grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4).
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.
Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.